Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older

NCT00460486 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00460486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00460486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
Not reported
Enrollment
330
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

encephalitis, tick-borne